Content about Pharmaceutical industry

November 19, 2012
Generic Drug Report 2012

The year 2012 is coming to an end, and it's been a big year for generic drugs. It's the year that the most lucrative drug of all time became commoditized. It's the year that Watson bought Actavis for $5.6 billion. And it's the year the FDA released draft guidance for biosimilars regulations. All of these events speak to some of the most important trends in the world of generics — trends that are often interrelated.

April 22, 2012
Consumer care

A lot has happened across GlaxoSmithKline’s consumer division in the past year. Drug Store News spoke with GSK Consumer chief marketing officer John Graham and chief customer officer Keith Loranger about the next move to be made out of the consumer division’s new playbook.

June 19, 2013
Most wasteful healthcare spending results from poor adherence, study finds

More responsible use of drugs could save the U.S. healthcare system more than $200 billion per year, according to a new study by the research arm of IMS Health.

June 18, 2013
Teva to acquire MicroDose for up to $165 million

Teva Pharmaceutical Industries will spend up to $165 million to buy a company developing a drug to prevent viral respiratory infections.

June 18, 2013
With nuanced ruling on ‘pay for delay,’ Supreme Court hands generics partial resolution

Half a loaf, the saying goes, is better than none. For the generic drug industry, that means that the Supreme Court handed it a partial victory Monday by ruling that “pay for delay” patent settlements between brand name and generic drug companies aren’t necessarily illegal and should be considered on a case-by-case, “rule of reason” approach by the Federal Trade Commission, which staunchly opposes the practice.

June 17, 2013
Award-winning McKesson Patient Relationship Solutions on display at McKesson ideaShare 2013

One of the greatest challenges facing the pharmaceutical industry today is medication nonadherence — a fact that has not gone unnoticed by McKesson.

A variety of pharmacy-based solutions, designed to help pharmacy owners drive better results both from a patient outcomes and a profitability standpoint by offering services that promote long-term adherence and opportunities for patients to enroll in clinical trials, will be on display for ideaShare attendees through McKesson’s Clinical Services network.

June 17, 2013
J&J to buy Aragon Pharmaceuticals for up to $1 billion

Drug maker Johnson & Johnson plans to spend up to $1 billion to acquire a privately owned company developing a drug for prostate cancer.

June 17, 2013
Supreme Court issues 'pay-for-delay' ruling

Patent settlements between brand and generic drug makers commonly referred to as "pay-for-delay" settlements are not necessarily against the law, the Supreme Court ruled Monday.

June 13, 2013
Actavis partners with Medicines360 to sell low-cost IUDs in public clinics

Drug maker Actavis is working with nonprofit pharmaceutical company Medicines360 to make low-cost intrauterine devices available to women, the two said.

June 13, 2013
FDA approves Amgen's Xgeva for giant cell tumor of the bone

The Food and Drug Administration has approved a drug made by Amgen for treating a rare and usually noncancerous bone tumor, the agency said Thursday.

June 12, 2013
PhRMA: 215 drugs under development for cardiovascular disease

More than 200 drugs are under development for cardiovascular disease, according to a drug industry trade group.

June 12, 2013
Teva, Sun to pay $2.15 billion to Pfizer, Takeda to settle Protonix case

Pfizer will receive more than $2 billion from Teva Pharmaceutical Industries and Sun Pharmaceutical Industries to settle a case concerning a gastroesophageal reflux disease drug.

June 10, 2013
AstraZeneca to buy developer of COPD drug

Anglo-Swedish drug maker AstraZeneca will pay up to $1.15 billion for a U.S. developer of drugs for respiratory diseases, AstraZeneca said Monday.

June 10, 2013
Avandia could get a second chance, following FDA panel vote

A 26-member joint panel comprising the Food and Drug Administration's Endocrinologic and Metabolic Drugs and Drug Safety and Risk Management advisory committees voted to support modifying or removing the risk evaluation and mitigation strategy protocol for GlaxoSmithKline's Type 2 diabetes drug Avandia (rosiglitazone).

Historically, the FDA has followed advisory committee votes when making a decision on the marketing of a drug even though it is not bound by them, but assuming the agency follows the panel's advice, it could mean a lot for the controversial drug and the way it's dispensed. But even if Avandia winds up on retail pharmacy shelves again, it faces a very different landscape from its heyday.

June 7, 2013
Actavis seeks approval for two generics

Actavis is hoping to become the first to market generic versions of a contraceptive and a sedative, the drug maker said.

June 7, 2013
Avandia could remain available following FDA advisory committee vote

A joint Food and Drug Administration expert panel voted to recommend keeping a controversial GlaxoSmithKline diabetes drug available for certain patients, GSK said.

June 5, 2013
Generic heartburn drug made by Korean company poised to win FDA approval

South Korean drug maker Hanmi Pharmaceutical Co. and U.S. partner Amneal Pharmaceuticals have made an agreement in federal court concerning a generic heartburn drug.

June 4, 2013
Boehringer Ingelheim's Robert Belknap honored with 2013 Nexus Award for Lifetime Achievement

The Center for Healthcare Supply Chain Research, HDMA’s nonprofit research foundation, and Genentech on Tuesday honored Robert Belknap, executive director of trade sales and operations for Boehringer Ingelheim Pharmaceuticals, with the 2013 Nexus Award for Lifetime Achievement.

June 4, 2013
House passes drug-tracing legislation

The House of Representatives voted Monday to pass a bill that would establish national standards for the pharmaceutical supply chain.

June 4, 2013
Rising Pharmaceuticals launches generic allergy drug

A subsidiary of Aceto Corp. has launched a generic treatment for seasonal and perennial allergies, the company said Tuesday.

June 3, 2013
Dr. Reddy's, Fujifilm end Japan generics deal

Dr. Reddy's Labs and Fujifilm have terminated a deal to market generic drugs in Japan, Dr. Reddy's said.

May 31, 2013
Reports: Sun to buy Meda for up to $6 billion

India-based Sun Pharmaceutical Industries may buy Sweden-based Meda for $5 billion to $6 billion, according to published reports.

May 30, 2013
Generic drug reimbursement cuts draw anger, controversy in Canada

When does the double-edged sword of generic drug price reductions begin to cut the government agency or health system holding the sword?

That's the question many pharmacy leaders in Canada have for the provincial health system policy-makers who have embarked on a crusade to whack pharmacy reimbursement levels for many lower-cost generic medicines sold under the nation's publicly funded health system.

May 30, 2013
Liability of harmful side effects questioned

This summer, the Supreme Court will decide on a case that could determine whether generic drug makers can be held liable when patients suffer harmful side effects from taking their drugs.

May 30, 2013
SCOTUS, biosimilars focus in 2013

The year is only halfway done, but 2013 is already proving to be a year of particular importance for generic drugs as the industry awaits two important decisions from the Supreme Court and continues to wait for federal biosimilar regulations while fending off efforts to limit the scope of their use at the state level.

© 2013 Drug Store News. All Rights Reserved.